Pure Bioscience, Inc.
PURE· OTC
PUREPure Bioscience, Inc.
Filed Dec 15, 2025 · 10-Q · 45 days after period end · 0001493152-25-027749
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $708.00K | $556.00K | $722.00K | $471.00K |
| Net Income | -$464.00K | -$689.00K | -$735.00K | -$993.00K |
| EPS Diluted | $0.00 | -$0.01 | -$0.01 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
ended Oct 31, 2025 · filed Dec 15, 2025 · 45 d after period end
